

References

Chapter 14

- 1 Kennedy PJ, Leathley CM, Hughes CF. Clinical practice variation. *Medical Journal of Australia*. 2010;**193**(8 Suppl.):S97–9.
- 2 Bergman U. The history of the Drug Utilization Research Group in Europe. *Pharmacoepidemiology and Drug Safety*. 2006;**15**(2):95–8.
- 3 Carstairs V. Small area analysis and health service research. *Community Medicine*. 1981;**3**(2):131–9.
- 4 Zhang Y, Baicker K, Newhouse JP. Geographic variation in Medicare drug spending. *New England Journal of Medicine*. 2010;**363**(5):405–9.
- 5 Zhang Y, Baicker K, Newhouse JP. Geographic variation in the quality of prescribing. *New England Journal of Medicine*. 2010;**363**(21):1985–8.
- 6 Donohue JM, Morden NE, Gellad WF, Bynum JP, Zhou W, Hanlon JT, et al. Sources of regional variation in Medicare Part D drug spending. *New England Journal of Medicine*. 2012;**366**(6):530–8.
- 7 Arnlind MH, Wettermark B, Nokela M, Hjemdahl P, Rehnberg C, Jonsson EW. Regional variation and adherence to guidelines for drug treatment of asthma. *European Journal of Clinical Pharmacology*. 2010;**66**(2):187–98.
- 8 Piovani D, Clavenna A, Bonati M. Drug use profile in outpatient children and adolescents in different Italian regions. *BMC Pediatrics*. 2013;**13**:46.
- 9 Neovius M, Sundstrom A, Simard J, Wettermark B, Cars T, Feltelius N, et al. Small-area variations in sales of TNF inhibitors in Sweden between 2000 and 2009. *Scandinavian Journal of Rheumatology*. 2011;**40**(1):8–15.
- 10 Palesh M, Jonsson PM, Jamshidi H, Wettermark B, Tomson G, Fredrikson S. Diffusion of interferon beta in Iran and its utilization in Tehran. *Pharmacoepidemiology and Drug Safety*. 2008;**17**(9):934–41.
- 11 Kloos H, Assefa Y, Aduagna A, Mulatu MS, Mariam DH. Utilization of antiretroviral treatment in Ethiopia between February and December 2006: spatial, temporal, and demographic patterns. *International Journal of Health Geographics*. 2007;**6**:45.
- 12 Parsons A, Johnstone A. Postcode prescribing and the Human Rights Act 1998. *Journal of the Royal Society of Medicine*. 2001;**94**(4):159–60.
- 13 Vander Stichele RH, Elseviers MM, Ferech M, Blot S, Goossens H. European surveillance of antimicrobial consumption (ESAC): data collection performance and methodological approach. *British Journal of Clinical Pharmacology*. 2004;**58**(4):419–28.
- 14 European Surveillance of Antimicrobial Consumption: ESAC I Final Report. 2004.
- 15 The EURO-MED-STAT Group. EURO-MED-STAT: monitoring expenditure and utilization of medicinal products in the European Union countries: a public health approach. *European Journal of Public Health*. 2003;**13**(3 Suppl.):95–100.
- 16 The Pharmacoepidemiological Research on Outcomes of Therapeutics by a European Consortium (PROTECT) (last accessed 20 December 2015)
- 17 Grimsson A, Idänpään Heikkilä J, Lunde PKM, Olafsson O, Westerholm B. The Utilization of Psychotropic Drugs in Finland, Iceland, Norway and Sweden. Studies in Drug Utilization. WHO Regional Publications. European Series No 8. Copenhagen, World Health Organization, Regional Office for Europe, 1979.
- 18 WHO Drug Utilization Research Group (DURG): Griffiths K, McDevitt DG, Andrew M, Baksaas I, Lunde PK, Bergman U, et al. Validation of observed differences in the utilization of antihypertensive and antidiabetic drugs in Northern Ireland, Norway and Sweden. *European Journal of Clinical Pharmacology*. 1985;**29**:1–8.
- 19 WHO Drug Utilization Research Group (DURG): Griffiths K, McDevitt DG, Andrew M, Baksaas I, Helgeland A, Jervell J, et al. Therapeutic traditions in Northern Ireland, Norway and Sweden:

- I. Diabetes. *European Journal of Clinical Pharmacology*. 1986;**30**:513–19.
- 20 WHO Drug Utilization Research Group (DURG): Griffiths K, McDevitt DG, Andrew M, Baksaas I, Helgeland A, Jervell J, et al. Therapeutic traditions in Northern Ireland, Norway and Sweden: II. Hypertension. *European Journal of Clinical Pharmacology*. 1986;**30**:521–5.
- 21 Gillström A, Wettermark B. Literature review: cross-national comparison of DU activities. Publication from the European Scientific Meeting of Drug Utilization ‘Better Public Health through Pharmacoevidence and Quality Use of Medicine’, Antwerp, Belgium, 2011.
- 22 Poluzzi E, Raschi E, Koci A, Moretti U, Spina E, Behr ER, et al. Antipsychotics and torsadogenic risk: signals emerging from the US FDA Adverse Event Reporting System database. *Drug Safety*. 2013;**36**(6):467–79.
- 23 Raschi E, Poluzzi E, Godman B, Koci A, Moretti U, Kalaba M, et al. Torsadogenic risk of antipsychotics: combining adverse event reports with drug utilization data across Europe. *PLoS ONE*. 2013;**8**:e81208.
- 24 Poluzzi E, Raschi E, Godman B, Koci A, Moretti U, Kalaba M, et al. Pro-arrhythmic potential of oral antihistamines (H1): combining adverse event reports with drug utilization data across Europe. 2015;**10**(3):e0119551.
- 25 Godman B, Shrank W, Andersen M, Berg C, Bishop I, Burkhardt T, et al. Comparing policies to enhance prescribing efficiency in Europe through increasing generic utilisation: changes seen and global implications. *Expert Reviews in Pharmacoeconomics Outcomes Research*. 2010;**10**:707–22.
- 26 Godman B, Shrank W, Andersen M, Berg C, Bishop I, Burkhardt T, et al. Policies to enhance prescribing efficiency in Europe: findings and future implications. *Frontiers in Pharmacology*. 2011;**1**:1–16.
- 27 Avorn J, Monette J, Lacour A, Bohn RL, Monane M, Mogun H, LeLorier J. Persistence of use of lipid-lowering medications: a cross-national study. *Journal of the American Medical Association*. 1998;**279**:1458–62.
- 28 Jackevicius CA, Tu JV, Ross JS, Ko DT, Krumholz HM. Use of ezetimibe in the United States and Canada. *New England Journal of Medicine*. 2008;**358**:1819–28.
- 29 Oei PL, Ratnam SS. Hormone replacement therapy in the developing countries. *Australian & New Zealand Journal of Obstetrics & Gynaecology*. 1998;**38**(2):141–4.
- 30 Chong MY, Tan CH, Fujii S, Yang SY, Ungvari GS, Si T, et al. Antipsychotic drug prescription for schizophrenia in East Asia: rationale for change. *Psychiatry and Clinical Neurosciences*. 2004;**58**(1):61–7.
- 31 Uchida N, Chong MY, Tan CH, Nagai H, Tanaka M, Lee MS, et al. International study on antidepressant prescription pattern at 20 teaching hospitals and major psychiatric institutions in East Asia: Analysis of 1898 cases from China, Japan, Korea, Singapore and Taiwan. *Psychiatry and Clinical Neurosciences*. 2007;**61**(5):522–8.
- 32 Chua KL, Soh SE, Ma S, Lee BW. Pediatric asthma mortality and hospitalization trends across Asia Pacific: relationship with asthma drug utilization patterns. *World Allergy Organization Journal*. 2009;**2**(5):77–82.
- 33 Andersen M, Bergman U, Choi NK, Gerhard T, Huang C, Jalbert J, et al. The Asian Pharmacoevidence Network (AsPEN): promoting multi-national collaboration for pharmacoepidemiologic research in Asia. *Pharmacoepidemiology and Drug Safety*. 2013;**22**(7):700–4.
- 34 Durán CE, Christiaens T, Acosta Á, Vander Stichele R. Systematic review of cross-national drug utilization studies in Latin America: methods and comparability. *Pharmacoepidemiology and Drug Safety*. 2015. doi: 10.1002/pds.3896.
- 35 Hogerzeil HV, Bimo, Ross-Degnan D, Laing RO, Ofori-Adjei D, Santoso B, et al. Field tests for rational drug use in twelve developing countries. *Lancet*. 1993;**342**(8884):1408–10.
- 36 Borg MA, Zarb P, Ferech M, Goossens H. Antibiotic consumption in southern and eastern Mediterranean hospitals: results from the ARMed project. *Journal of Antimicrobial Chemotherapy*. 2008;**62**(4):830–6.
- 37 Lupattelli A, Spigset O, Twigg MJ, Zagorodnikova K, Mardby AC, Moretti ME, et al. Medication use in pregnancy: a cross-sectional, multinational web-based study. *British Medical Journal Open*. 2014;**4**(2):e004365.
- 38 Utilization of antiepileptic drugs during pregnancy: comparative patterns in 38 countries based on data from the EURAP registry. *Epilepsia*. 2009;**50**(10):2305–9.
- 39 Ferrer P, Ballarín E, Sabaté M, Laporte JR, Schoonen M, Rottenkolber M, et al. Sources of European drug consumption data at a country level. *International Journal of Public Health*. 2014;**59**(5):877–87.

- 40 Sabaté M, Ferrer P, Ballarín E, Rottenkolber M, Amelio J, Schmiendl S, et al.; PROTECT Work Package 2. Inpatient drug utilization in Europe: nationwide data sources and a review of publications on a selected group of medicines (PROTECT Project). *Basic Clinical Pharmacology & Toxicology*. 2015;**116**(3):201–11.
- 41 Vander Stichele RH, Peys F, Van Tielen R, Van Eeckhout H, van Essche O, Seys B. A decade of growth in public and private pharmaceutical expenditures: the case of Belgium 1990–1999. *Acta Clinica Belgica*. 2003;**58**(5):279–89; disc. 7–8.
- 42 Jonsson B, Kobelt G, Smolen J. The burden of rheumatoid arthritis and access to treatment: uptake of new therapies. *European Journal of Health Economics*. 2008;**8**(Suppl. 2):S61–86.
- 43 Molstad S, Lundborg CS, Karlsson AK, Cars O. Antibiotic prescription rates vary markedly between 13 European countries. *Scandinavian Journal of Infectious Diseases*. 2002;**34**(5):366–71.
- 44 Walley T, Folino-Gallo P, Stephens P, Van Ganse E. Trends in prescribing and utilization of statins and other lipid lowering drugs across Europe 1997–2003. *British Journal of Clinical Pharmacology*. 2005;**60**(5):543–51.
- 45 Neubert A, Verhamme K, Murray ML, Picelli G, Hsia Y, Sen FE, et al. The prescribing of analgesics and non-steroidal anti-inflammatory drugs in paediatric primary care in the UK, Italy and the Netherlands. *Pharmacological Research*. 2010;**62**(3):243–8.
- 46 Obradovic M, Mrhar A, Kos M. Market uptake of biologic and small-molecule – targeted oncology drugs in Europe. *Clinical Therapeutics*. 2009;**31**(12):2940–52.
- 47 Hoebert JM, Mantel-Teeuwisse AK, van Dijk L, Laing RO, Leufkens HG. Quality and completeness of utilisation data on biological agents across European countries: tumour necrosis factor alpha inhibitors as a case study. *Pharmacoepidemiology and Drug Safety*. 2011;**20**(3):265–71.
- 48 Walley T, Folino-Gallo P, Schwabe U, Van Ganse E, Stephens P. Comparison of national administrative and commercial databases to monitor expenditure and costs of statins across Europe. *European Journal of Clinical Pharmacology*. 2004;**60**(7):503–11.
- 49 Ronning M, Blix HS, Harbo BT, Strom H. Different versions of the anatomical therapeutic chemical classification system and the defined daily dose – are drug utilisation data comparable? *European Journal of Clinical Pharmacology*. 2000;**56**(9–10):723–7.
- 50 Ballarín E, Ferrer P, Sabaté M, Petri H, Rottenkolber M, Fortuny J, et al. A proposed checklist to interpret cross-national comparison studies of drug utilization. Available from: <http://www.imi-protect.eu/documents/Ballarinetal-AproposedchecklistICPE2012.pdf> (last accessed 18 November 2015).
- 51 Stolk P, Van Wijk BL, Leufkens HG, Heerdink ER. Between country variation in the utilization of antihypertensive agents: guidelines and clinical practice. *Journal of Human Hypertension*. 2006;**20**:917–22.
- 52 Deschepper R, Grigoryan L, Lundborg CS, Hofstede G, Cohen J, Van Der Kelen G, et al. Are cultural dimensions relevant for explaining cross-national differences in antibiotic use in Europe? *BMC Health Services Research*. 2008;**8**:123.
- 53 Ferrer P, Raffaniello C, Sabaté M, Ballarín E, Coma A, Corinne Z. Cross-national comparison of antiepileptic drug use: Catalonia, Denmark and Norway, 2007–2011. *Epidemiology Biostatistics and Public Health*. 2014;**11**(3).
- 54 Marshall MN, Shekelle PG, McGlynn EA, Campbell S, Brook RH, Roland MO. Can health care quality indicators be transferred between countries? *Quality & Safety in Health Care*. 2003;**12**:8–12.
- 55 Hoven JL, Haaijer-Ruskamp FM, Vander Stichele RH. Indicators of prescribing quality in drug utilisation research: report of a European meeting (DURQUIM, 13–15 May 2004). *European Journal of Clinical Pharmacology*. 2005;**60**(11):831–4.
- 56 EURO-MED-STAT Group. EURO-MED-STAT: Recommendations for National Registers of Medicinal Products with Validated ATC Codes and DDD Values. Final version, March 2004.
- 57 Furu K, Wettermark B, Andersen M, Martikainen JE, Almarsdottir AB, Sorensen HT. The Nordic countries as a cohort for pharmacoepidemiological research. *Basic & Clinical Pharmacology & Toxicology*. 2010;**106**(2):86–94.
- 58 Wettermark B, Zoega H, Furu K, Korhonen M, Hallas J, Norgaard M, et al. The Nordic prescription databases as a resource for pharmacoepidemiological research – a literature review. *Pharmacoepidemiology and Drug Safety*. 2013;**22**(7):691–9.

- 59 Wirtz VJ, Reich MR, Leyva-Flores R, Dreser A. Medicines in Mexico, 1990–2004: systematic review of research on access and use. *Salud Pública de Mexico*. 2008;**50**(Suppl. 4):S470–9.
- 60 Mousavi S, Mansouri A, Jahangard-Rafsanjani Z, Sarayani A, Hadjibabaie M, Gholami K. Bibliographic search of publication patterns in rational use of drugs in Iran: a systematic approach. *Acta Medica Iranica*. 2014;**52**(1):76–81.